Chugai, Taisho Of Japan To Seek Osteo Drug Approval By Year's End
This article was originally published in PharmAsia News
Executive Summary
Japan's Chugai Pharmaceutical and Taisho Pharmaceutical, joint developers of an osteoporosis drug, plan to apply for approval in Japan by the end of this year. The companies made the decision based on Phase III trials that returned positive results. Chugai created the drug that helps promote absorption of calcium and bone formation, and Taisho helped it take the drug through trials that compared it with existing drugs. The two firms have other osteoporosis drugs in joint development. (Click here for more - a subscription may be required